BioCentury
ARTICLE | Product Development

Novavax redesigns U.K. trial to align with global COVID-19 vaccine trials

Company expects to start U.S. pivotal trial at end of November

October 28, 2020 9:55 PM UTC

Novavax has modified the U.K. Phase III trial of its COVID-19 vaccine candidate to ensure that it could support EMA approval and, the company believes, potentially support authorization or approval in the U.S.

EMA recommended changes to the design of the U.K. Phase III trial of NVX-CoV2373 to align with trials that are being conducted by other manufacturers around the world, Gregory Glenn, president for R&D at Novavax Inc. (NASDAQ:NVAX), told BioCentury. ...